Integrating digital phenotyping in clinical characterization of individuals with mood disorders.

Neurosci Biobehav Rev

Department of Psychiatry, Providence Care Hospital, Queen's University School of Medicine, Kingston ON, Canada; Canadian Biomarker Integration Network in Depression (CAN-BIND) at Queen's University and Providence Care Hospital, Kingston, ON, Canada. Electronic address:

Published: September 2019

Major Depressive Disorder (MDD) and bipolar disorder (BD) are still under recognized and undertreated, especially in primary care settings. One of the challenges faced by clinicians is the remarkable inter-individual variability among patients with these conditions. In addition, each patient with MDD and BD experiences a unique pattern of longitudinal changes across time, i.e., intra-individual variability can also be problematic. The immense amount of data generated and collected through the use of smartphones or personal devices offers an opportunity to obtain continuous and reliable information on each individual's behavior, a less burdensome way to capture both intra and inter-individual variability over time. Digital phenotypes (DP) are a promising strategy to be integrated with other "Omics" platforms for prediction of relevant outcomes in mood disorders, including but not restricted to, relapse, recurrence, cognitive decline and functional impairment. Despite existing limitations and some skepticism, digital phenotyping represents a field in great expansion and might eventually constitute a feasible strategy in biomarkers research for mood disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neubiorev.2019.07.009DOI Listing

Publication Analysis

Top Keywords

mood disorders
12
digital phenotyping
8
inter-individual variability
8
integrating digital
4
phenotyping clinical
4
clinical characterization
4
characterization individuals
4
individuals mood
4
disorders major
4
major depressive
4

Similar Publications

Seltorexant for major depressive disorder.

Expert Opin Emerg Drugs

January 2025

Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

Introduction: Preclinical and clinical pharmacologic evidence indicate that orexin systems are relevant to sleep-wake cycle regulation and dimensions of reward and cognition, providing the basis to hypothesizing that they may be effective as therapeutics in mental disorders. Due to the limited efficacy and tolerability profiles of existing treatments for Major Depressive Disorder (MDD), investigational compounds in novel treatment classes are needed; seltorexant, an orexin receptor antagonist, is a potential new treatment currently under investigation.

Areas Covered: Mechanisms implicated in MDD, including reward and sleep are first overviewed.

View Article and Find Full Text PDF

Positive associations between mean ambient temperature and involuntary admissions to psychiatric facilities.

Eur Psychiatry

January 2025

Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.

Background: Temperature increases in the context of climate change affect numerous mental health outcomes. One such relevant outcome is involuntary admissions as these often relate to severe (life)threatening psychiatric conditions. Due to a shortage of studies into this topic, relationships between mean ambient temperature and involuntary admissions have remained largely elusive.

View Article and Find Full Text PDF

Lithium is used in the treatment of bipolar disorder to manage and stabilize mood, proving effective in addressing both manic and depressive phases. In these patients, the use of lithium is associated with various thyroid disorders, such as goiter and hypothyroidism; thyrotoxicosis is a rare presentation. In this case report, we demonstrated lithium-induced thyroiditis on thyroid scintigraphy.

View Article and Find Full Text PDF

Background: Improving functioning in adults with major depressive disorder (MDD) and bipolar disorder (BD) is a priority therapeutic objective.

Methods: This retrospective post hoc secondary analysis evaluated 108 patients with MDD or BD receiving the antidepressants vortioxetine, ketamine, or infliximab. The analysis aimed to determine if changes in objective or subjective cognitive function mediated the relationship between depression symptom severity and workplace outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!